The Best Storage Beds That Help Reduce Bedroom Clutterhttps://t.co/FiJH07vmPb https://t.co/5VkWQm4Qts ...

The 7 Best Cooling Dog Beds To Give Pups Relief In Summer Heathttps://t.co/jFnGiJiq0t https://t.co/fwjWIx5Wo9 ...

RT useless coin (@theuselesscoin)BREAKING: USELESS coin (153m market cap) has now flipped Sleep Number Corp ($152m market cap).While they sold $1.68B worth of smart beds that adjust while you sleep, USELESS coin offers nothing at all.The world has spoken. Useless wins again. ...

The Zacks Furniture industry is thriving through digital transformation, with investments in e-commerce, augmented reality (AR), and artificial intelligence (AI) improving customer experiences and operations. Demand for multifunctional furniture is rising, especially among millennials and Gen Z. Companies like Sleep Number Corporation (SNBR) and Virco Mfg. Corporation (VIRC) are focusing on innovation, digital marketing and strategic acquisitions to expand their product portfolios and market reach.Despite e ...

Summary of Central Garden & Pet Company (CENT) FY Conference Company Overview - **Company**: Central Garden & Pet Company (CENT) - **Date of Conference**: June 09, 2025 - **Key Speaker**: Brad Smith, CFO Key Points Management Changes and Strategy - Recent management changes include Nico becoming CEO and Brad Smith as CFO, with a focus on transitioning to a more agile culture that empowers business units (BUs) to make decisions [5][6] - The core strategy remains consistent, emphasizing innovation alongside cost reduction, which has become part of the company's DNA [7][8] - Mergers and Acquisitions (M&A) will focus on pet consumables and adjacent markets, moving beyond traditional pet and garden spaces [8][9] Pet Segment Dynamics - The pet segment is bifurcated into consumables and durables, with consumables showing resilience, particularly in dog and cat products [12][13] - Pet ownership demand is stabilizing, with dog ownership slightly below pre-pandemic levels and cat ownership slightly above [12][29] - Durables have contracted from approximately 35% of total pet sales during the pandemic to below 20%, attributed to declining demand and strategic consolidation [14][18] - The company is optimizing its durable product offerings to maintain profitability amidst increased competition from overseas [22][23] Garden Segment Dynamics - The garden business is highly weather-dependent, with sales fluctuating based on weather conditions [34][35] - Recent weather patterns have been challenging, impacting sales negatively, but there is potential for an extended selling season if favorable weather occurs [38][39] - The wild bird feed segment has performed well, countering the overall weather-related challenges [44][46] Market and Economic Factors - Tariffs and trade policies have impacted demand for durable products, leading to a shift in sourcing to countries with lower tariffs [25][26] - The stagnant housing market affects larger garden projects, with HELOC rates influencing consumer spending on major renovations [48] M&A and Growth Opportunities - M&A remains a priority, with a focus on pet consumables, particularly in the dog and cat segments, and potential growth in supplements [49][51] - The company is exploring adjacencies, such as pest control products, to expand its market reach [54] Retail and Distribution - The company continues to grow its online presence while facing challenges in the pet specialty retail channel [56][58] - Partnerships with large retailers like Walmart and Costco remain strong, with a shift towards online sales expected to continue [59] Capital Allocation - Priorities for capital allocation include M&A, internal investments for growth, and share buybacks, with a current focus on M&A opportunities [60] Additional Insights - The company is optimistic about the potential for growth in the pet consumables market, particularly in the cat segment, which has been underrepresented [52] - The psychological factors driving demand for wild bird feed indicate a growing consumer interest in this category [45]

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves a ...

Core Points - Savaria Corporation, a global leader in the accessibility industry, held its Annual General Meeting of Shareholders where all nominated directors were elected [1][2] - The voting results showed high approval rates for the nominees, with Pernilla Lindén receiving 99.81% in favor, while Alain Tremblay had the lowest approval at 81.24% [2] Group 1: Election of Directors - All nominees listed in the Management Proxy Circular were elected as directors by a majority resolution [2] - Caroline Bérubé received 95.18% in favor, while Jean-Marie Bourassa received 95.48% [2] - The lowest approval was for Alain Tremblay at 81.24%, with 41,500,260 votes in favor [2] Group 2: Company Overview - Savaria Corporation provides accessibility solutions for the physically challenged, enhancing comfort, mobility, and independence [3] - The company offers a comprehensive product line including stairlifts, wheelchair lifts, elevators, and medical equipment [3] - Savaria operates a global sales network with approximately 2,500 employees and manufacturing plants in multiple countries including Canada, the US, Mexico, Europe, and China [3]

Financial Data and Key Metrics Changes - Q1 2025 revenue was $1,040 million, down 1.4% year over year, with constant currency revenue roughly flat [19][30] - Non-GAAP EPS was $0.97, at the high end of guidance [18][27] - Non-GAAP gross margin increased by 30 basis points year over year to 67.4% [24] - Non-GAAP operating margin was 20.4% in Q1 [27] - Cash flow from operations was $240 million, with free cash flow at $208 million [28] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $696 million, growing approximately 1% year over year [19] - Sequencing instruments revenue was approximately flat at $109 million [22] - Sequencing service and other revenue decreased by approximately 5% year over year to $142 million [23] Market Data and Key Metrics Changes - Clinical business consumables grew mid-single digits, while research consumables were down in the high mid to high single-digit range [49] - The Greater China region is expected to contribute only $165 million to $185 million in full-year revenue, significantly down from previous levels [30][32] Company Strategy and Development Direction - The company aims for high single-digit revenue growth and 500 basis points margin expansion by 2027, excluding Greater China [8][10] - A $100 million cost reduction program was initiated to address challenges in China and the U.S. funding environment [11][25] - The company is focused on advancing its Multiomics ecosystem and has several new product launches planned for 2025 and 2026 [13][16] Management's Comments on Operating Environment and Future Outlook - Management acknowledged macroeconomic challenges but emphasized the resilience of the business and strong sequencing activity [6][44] - The company is actively engaging with regulatory authorities in China to find long-term solutions [10][32] - Management expressed confidence in the long-term growth trajectory despite current headwinds [9][39] Other Important Information - The company is revising its guidance to reflect geopolitical impacts, particularly in China [29] - The estimated gross cost of tariffs for 2025 is approximately $85 million, impacting margins [34][35] Q&A Session Summary Question: What is the outlook for revenue growth and margins? - Management believes revenue growth will rebound and margins will expand above 25% in the future, with a focus on cost control [41][42] Question: What are the growth rates for clinical and research segments? - Clinical revenue grew mid-single digits, while research revenue is expected to decline in the mid-double digits for the remainder of the year [49][50] Question: How are tariffs affecting demand? - No significant change in customer behavior was observed in Q1 due to tariffs, but future impacts are anticipated [66][68] Question: What is the impact of China on future revenue? - The company expects continued revenue decline from China, with proactive measures in place to mitigate risks [96]

LAVAL, Québec, May 07, 2025 (GLOBE NEWSWIRE) -- Savaria Corporation (“Savaria”) (TSX: SIS), one of the global leaders in the accessibility industry, is pleased to announce its results for the first quarter of 2025. Highlights – Q1 2025 compared to Q1 2024 Revenue was $220.2M, up $10.8M or 5.2%, mainly due to a positive foreign exchange impact of 3.3%, and organic growth of 0.8%. The revenue benefited from the contribution of Matot acquired last year. Accessibility experienced growth of 6.1%, including growt ...

A downtrend has been apparent in Sleep Number (SNBR) lately. While the stock has lost 7.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case for the ...